The gender distribution revealed that 57.5% of reports involved female patients, while male patients accounted for 40.5%, with the remaining 2.0% lacking gender specification
Due to TriNetxs data sharing policies, we do not have access to individual-level data
Disclaimer: For laboratory research and informational use only
Perez, who was not involved in the SYNCHRONIZE-1 trial, cautioned that the full data should be made available before any claims are made about its side effects
However, we acknowledge that such a caliper may exclude certain patients, potentially introducing selection bias and reducing generalizability
they must be applied in the appropriate amount so as not to damage the natural proportion of the face and reapplication at the proper time so as not to fall into excess and so that our body has already absorbed it in the greatest possible quantity